Welcome to Debate Club! Please be aware that this is a space for respectful debate, and that your ideas will be challenged here. Please remember to critique the argument, not the author.

The GLP-1 juggernaut is slowing. Eli Lily missed a sales target.

MargaretYakoda
MargaretYakoda Posts: 2,991 Member
in Debate Club
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling

https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-misses-third-quarter-profit-amid-soaring-demand-weight-loss-drug-2024-10-30/

Looks like there’s a limit to demand for GLP-1 meds.
Tagged:

Replies

  • SafariGalNYC
    SafariGalNYC Posts: 1,459 Member
    @MargaretYakoda interesting.

    Some off the cuff thoughts-

    At some point it has to be an oversaturated market.
    When we get to the point.. I don’t know.

    According to an article in cnbc today, Eli reps said it’s was a problem with “inventory stocking .”

    “The primary culprit was an inventory hit to Mounjaro and Zepbound ... not weaker demand," Citi analyst Geoff Meacham wrote in a research note Wednesday.

    Jared Holz, Mizuho health-care equity strategist, wrote in an email that "destocking" — or selling existing inventory for the drugs rather than stocking up on more — came as a surprise, especially with the high level of demand for the treatments.”


    =>Eli Lilly has invested $15 billion to expand manufacturing capacity for its injectable drugs for 24-25. Im sure we will be inundated with advertisements with happy skinny people.

    How much of the injectable - medicalized weight loss use is just great marketing?

Categories